10-Q quarterly report · filed Nov 10, 2026

PepGen Inc (PEPG) Q3 2026 10-Q Quarterly Report

Short answer

PepGen Inc (PEPG) filed its Q3 2026 10-Q quarterly report on Nov 10, 2026 for the quarter ended Sep 30, 2026.

Q3 2026 key financials · XBRL

Net income
−$19M
−7.6% YoY · −8.9% QoQ
EPS (diluted)
−$0.28
+45.1% YoY · −12.0% QoQ

Source: XBRL data from the PepGen Inc (PEPG) Q3 2026 10-Q on SEC EDGAR. USD.

PepGen Inc Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Revenue $0, unchanged YoY, no product sales since inception
  • Net loss $19.4M vs $18.0M YoY, operating loss $20.4M vs $18.7M
  • R&D expense $14.5M vs $13.4M, PGN-EDODM1 external expense $7.7M vs $5.4M
  • Cash, equivalents and marketable securities $104.8M at September 30, 2026, funding planned operations into 2028
  • Operating cash use $47.4M for nine months, ATM proceeds $1.5M, FREEDOM2 remains on partial U.S. clinical hold

Risk Factors

  • Newly added BIOSECURE Act risk: WuXi AppTec’s June 2026 Section 1260H designation could trigger OMB BCC designation and supplier transition costs
  • Regulatory risk: FDA partial clinical hold announced March 2026 requires additional nonclinical mouse studies for FREEDOM2
  • Operational risk: Single-source API and finished-product suppliers could disrupt PGN-EDODM1 clinical development
  • Financial risk: $104.8 million cash, equivalents and marketable securities as of September 30, 2026, with additional funding needed beyond 2026 readouts
  • Market risk: PGN-EDODM1 remains PepGen’s only active clinical program after PGN-EDO51 discontinuation in May 2025

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.